ScinoPharm Becomes the First Taiwanese Company to Win US FDA Approval for Glatiramer Acetate

ScinoPharm Becomes the First Taiwanese Company to Win US FDA Approval for Glatiramer Acetate

By, Admin 5 January 2026

ScinoPharm Taiwan has achieved a historic milestone. The company has secured US FDA approval for Glatiramer Acetate Injection, a complex generic used to treat Multiple Sclerosis (MS). No other pharmaceutical company in Taiwan has reached this benchmark before.

This approval positions ScinoPharm among a very small global group capable of manufacturing this product at scale.

Why This Approval Matters?

Multiple Sclerosis is a large and growing disease area.

  • ~2.9 million patients globally
  • ~1 million patients in the US alone
  • Global Glatiramer Acetate market valued at USD 1.5 billion in 2024
  • Projected to reach USD 2.8 billion by 2033

The US market alone is worth ~USD 700 million, making FDA approval strategically critical.

Glatiramer Acetate: One of the Hardest Generics to Make

Glatiramer Acetate is not a typical generic drug. It is classified by the FDA as a Non-Biological Complex Drug (NBCD).

Key challenges include:

  • Not a single molecule, but millions of peptide variants
  • No fixed molecular structure or sequence
  • Cannot be fully characterized like biologics or small molecules

Quality, consistency, and equivalence are exceptionally difficult to prove.

The Science Behind ScinoPharm’s Breakthrough

ScinoPharm spent years in R&D to crack this problem.

What it required:

  • 40+ advanced analytical techniques
  • Statistical modeling to ensure batch-to-batch consistency
  • Biological activity assays to confirm equivalence to Copaxone® (Teva)

Very few companies globally possess this capability today. ScinoPharm is now one of them.

What This Signals About ScinoPharm?

This approval is more than a single product win. It validates:

  • Deep expertise in complex generics
  • Strong integration across R&D, analytics, and manufacturing
  • Ability to compete with top global pharmaceutical players

For Taiwan’s pharma industry, this is a credibility inflection point.

What Comes Next: Global Expansion?

ScinoPharm is already moving beyond the US. Current priorities include:

  • Regulatory filings across Europe and Asia
  • Strategic partnerships in emerging markets
  • Expanding finished-dosage presence alongside its strong API business

The company’s stated mission remains clear: Deliver safe, effective, high-quality medicines through rigorous science.

Bottom Line

US FDA approval for Glatiramer Acetate puts ScinoPharm on the global map. It proves Taiwan can deliver world-class complex generics. And it opens the door to sustained growth in a multibillion-dollar market.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!